James Mulay, Director at CG Oncology, Inc. (CGON), sold 54,030 shares at $33.22 ($1.7M) on 2025-09-05, disclosed to the SEC on 2025-09-08.
Scheduled sale ($1.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.47 | 12,342 | $376K | 22.1% |
| 2 | $30.47 | 12,342 | $376K | 22.1% |
| 3 | $31.42 | 4,095 | $129K | 7.6% |
| 4 | $31.42 | 4,095 | $129K | 7.6% |
| 5 | $32.64 | 7,465 | $244K | 14.3% |
| 6 | $32.64 | 7,465 |
| $244K |
| 14.3% |
| 7 | $33.22 | 3,113 | $103K | 6.1% |
| 8 | $33.22 | 3,113 | $103K | 6.1% |
| Total | $31.53 avg | 54,030 | $1.7M | 100% |
| Filing → |
| CGON | SELL | 2026-04-20 | $1.1M | — | Filing → |
| CGON | SELL | 2026-03-17 | $125K | — | Filing → |
| CGON | SELL | 2026-01-13 | $585K | — | Filing → |